Sep 12, 2022 / 03:00PM GMT
Matt Keller - H.C. Wainwright & Co., LLC - Analyst
Good morning, everyone, and welcome to the H.C. Wainwright 24th Annual Global Investment Conference. My name is Matt Keller. I'm an associate in the equity research department.
With that said, I want to introduce our next presenter, Kristi Jones, the CEO of Neximmune. With that, Kristi, please take it away.
Kristi Jones - Neximmune, Inc. - CEO
Fantastic. Thank you so much for this invitation to speak at the conference. So great to be here in person and see friendly faces that we haven't been able to see in person for so long. And I think everybody's probably starting with something very similar to that.
So let me just start giving maybe a brief context of Neximmune. Our platform technology is called AIM, the Artificial Immune Modulating platform. Our vision is to drive cell-mediated immune responses that have potential for cure in various diseases specific -- that have engine-specific components.
Let me just kind of walk through a little bit about how that mechanism fits and
Neximmune Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers